Ireland· IE-PA-EU/1/22/1683/002
Vabysmo 120 mg/mL solution for injection in pre-filled syringe
A faricimab product containing faricimab, registered in Ireland by Roche Registration GmbH. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Faricimab is registered in 14 of 19 countries.
Countries holding a registration under ATC S01LA09 (faricimab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Faricimab · ATC S01LA09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Faricimab
- Manufacturer
- Roche Registration GmbH
- Country
- Ireland (IE)
- ATC code
- S01LA09
- ATC class
- Faricimab
- Defined daily dose
- 0.0357 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/22/1683/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Faricimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainVABYSMO 120 MG/ML SOLUCION INYECTABLERoche Registration Gmbh
- SwitzerlandVabysmo 6 mg/0,05 ml, InjektionslösungRoche Pharma (Schweiz) AG
- CzechiaVABYSMORoche Registration GmbH, Grenzach-Wyhlen
- BelgiumVabysmo 120 mg/mlRoche Registration
- IcelandVabysmoRoche Registration GmbH*
- NorwayVabysmoRoche Registration GmbH
- SwedenVABYSMO 120 mg/ml Injektionsvätska, lösningRoche Registration GmbH
- NetherlandsVabysmo 120 mg/ml, oplossing voor injectieRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vabysmo
- Liechtenstein · Vabysmo
- Norway · Vabysmo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e87b4f11-e23e-4a76-9039-8aa7a5a649a9 GET /v1/drugs/e87b4f11-e23e-4a76-9039-8aa7a5a649a9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"routes": [
"Intravitreal use"
],
"source": "hpra",
"atc_all": [
"S01LA09"
],
"strength": null,
"pa_number": "EU/1/22/1683/002",
"substances": [
"Faricimab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "15/09/2022",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about faricimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.